Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Vor Biopharma Inc.NASDAQ: VOR
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$1.37B, compared with -$489.48M a year earlier.
Context
- Retained earnings amounted to 270.9% of total assets at the end of Q1 FY2026, down 176.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -180.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (1.15B) USD
- Year-over-year change
- -152.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.15B) | -152.3% |
| FY2024 | 2024-12-31 | (456.99M) | -34.4% |
| FY2023 | 2023-12-31 | (340.08M) | -53.0% |
| FY2022 | 2022-12-31 | (222.22M) | -70.8% |
| FY2021 | 2021-12-31 | (130.12M) | — |
Retained Earnings vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's Mar 2026 retained earnings of -$1.37B is the 3rd highest of the 10 companies compared; the peer median is -$1.57B.
- Its year-over-year change of -180.4% is the lowest of 10, against a peer median of -16.4%.
- Retained earnings amounts to 270.9% of total assets for VOR, versus a peer median of 354.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$676.14M | -17.3% | — | 181.7% | |
| Mar 2026 | -$813.56M | -15.3% | — | 249.1% | |
| Mar 2026 | -$1.37B | -180.4% | — | 270.9% | |
| Mar 2026 | -$1.46B | -24.7% | — | 276.7% | |
| Mar 2026 | -$1.49B | -16.4% | — | 521.7% | |
| Mar 2026 | -$1.57B | -9.0% | — | 549.5% | |
| Mar 2026 | -$1.65B | -7.1% | — | 1107.2% | |
| Mar 2026 | -$1.9B | -14.6% | — | 507.6% | |
| Sep 2026 | -$2.27B | -25.1% | — | 88.9% | |
| Mar 2026 | -$2.69B | -17.2% | — | 354.0% | |
| Peer median (excluding VOR) | -$1.57B | -16.4% | — | 354.0% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 119.8M | 57.71M | 31.36M | 81.95M | 396.49M |
| Short-term Investments | 87.67M | 172.54M | 105.82M | 9.98M | 58.72M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.09M | 2.34M | 475K | 380K | 1.75M |
| Total Current Assets | 214.4M | 236.95M | 140.8M | 96.51M | 458.11M |
| Property, Plant & Equipment (Net) | 22.52M | 57.08M | 50.1M | 41.59M | 3.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 2.41M | 2.41M | 0 | 0 |
| Tax Assets | 0 | 0 | 11.7M | 0 | 0 |
| Other Non-current Assets | 5.67M | 2.93M | 4.81M | 4.8M | 2.55M |
| Total Non-current Assets | 28.19M | 62.42M | 69.03M | 46.38M | 6.02M |
| Total Assets | 242.59M | 299.37M | 209.83M | 142.89M | 464.13M |
| Account Payables | 1.55M | 1.77M | 815K | 1.51M | 5.13M |
| Short-term Debt | 0 | 0 | 3.83M | 0 | 280K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 434K | 4.95M | 4.97M | 6.21M | 15.33M |
| Total Current Liabilities | 10.15M | 13.12M | 15.57M | 18.61M | 25.17M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 11.7M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 600.55M |
| Total Non-current Liabilities | 16.17M | 35.64M | 43.53M | 27.62M | 603.27M |
| Total Liabilities | 26.33M | 48.76M | 59.1M | 46.23M | 628.44M |
| Common Stock | 4K | 7K | 7K | 13K | 18K |
| Retained Earnings | (130.12M) | (222.22M) | (340.08M) | (456.99M) | (1.15B) |
| Accumulated OCI | 0 | (770K) | (77K) | 22K | 41K |
| Other Stockholders Equity | (1K) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 216.26M | 250.61M | 150.72M | 96.66M | (164.31M) |
| Total Debt | 18.01M | 38.91M | 35.66M | 31.83M | 3M |
| Net Debt | (101.79M) | (18.79M) | 4.3M | (50.12M) | (393.49M) |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.